spacer
home > pmps > spring 2018 > controlled conduct
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Controlled Conduct

PMPS: Can you explain the current prevalence of counterfeiting within the pharmaceutical industry?

Sandra Lee: The WHO estimate 15% of all medicines available worldwide are counterfeit, and, while this decreases to around 1% in the EU, it remains a significant risk to patient safety. As the demand for prescription medicines continues to rise, incentive and opportunity for counterfeiters to interfere with the legitimate supply chain increases.

Pharma manufacturers have been preparing for the adoption of the Falsified Medicines Directive (FMD), which will be enforced in February 2019, as this will provide added security within the supply chain. The additional safeguards of FMD will help protect against counterfeit medicines potentially reaching critically ill patients, such as the recently reported instances of oncology medicines for cancer patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sandra Lee has 35 yearsí plus of operational, quality, and project management experience within the commercial and clinical pharma industry, gained through roles at past organisations such as Novartis, Boehringer Ingelheim, Fisher Clinical Services, and now Accord Healthcare. Currently, as the Managing Director of operations at Accord, she leads the manufacturing sites at Barnstaple and Haverhill. Sandra received her BSc in applied chemistry at Brighton Polytechnic, UK, has a post-graduate diploma in industrial pharmaceutical studies, and is also a Chartered Director.
spacer
Sandra Lee
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: itís where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on todayís hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement